Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(17s)-17-(((dimethoxyphosphoryl)methoxy)carbonyl)-3β-hydroxy-28-norurs-12(13)-ene is a semisynthetic pentacyclic triterpenoid derivative of ursolic acid. It is part of a series of methylphosphonate-functionalized triterpenoids synthesized to improve the pharmacological profile, particularly the bioavailability and anticancer potency, of naturally occurring triterpenic acids. The compound features a dimethylphosphonate moiety attached via an ester linkage at the C-17 position. Preclinical research indicates that this derivative possesses significant antineoplastic activity, specifically demonstrating dose-dependent inhibition of cell viability and migration in melanoma cell lines such as B164A5. Compared to its parent compound, ursolic acid, this derivative is designed for enhanced therapeutic efficacy while maintaining a favorable safety profile, as evidenced by its lack of significant irritant effects in HET-CAM assays and low cytotoxicity in non-malignant models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (17s)-17-(((dimethoxyphosphoryl)methoxy)carbonyl)-3β-hydroxy-28-norurs-12(13)-ene.